NEW ORLEANS--(BUSINESS WIRE)-- FibroGen, Inc. today announced that administration of investigational therapy FG-3019, a human monoclonal antibody against connective tissue growth factor (CTGF), ...
3037.TW Unimicron Technology Corp.
Clinical outcomes in pancreatic adenocarcinoma (PAC) associated with a known BRCA mutation. Background: CTGF is highly expressed in pancreatic tumors and is thought to mediate local desmoplasia.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results